Severe Traumatic Brain Injury
Conditions
Keywords
inflammatory Biomarkers, Traumatic brain injury, multimodal MRI, tertiary lesion
Brief summary
Tertiary lesions responsible of the neurological decline after severe traumatic brain injury (TBI) are partially due to a persistent neuro-inflammation directly modulated by inflammatory mediators during the acute phase and detectable by using both multimodal MRI imaging and biological biomarkers during the acute phase after traumatic brain injury. The main objective is to identify if the level of IL-1beta in cerebrospinal fluid predict in a reliable and reproducible way, the neuro-radiological evolution evaluated by the comparison of a quantitative MRI performed in post-resuscitation and at one year (quantitative ΔIRM) in traumatic brain injuried patients. The secondary objectives are: * To understand the links between the acute and chronic neuro-inflammatory phase in a population of TBI, * To explore the contribution of the adaptive immune response in the persistent activation of the immune response, * To Examine the links between persistent neuroinflammation, clinical deterioration and neuroimaging, * To establish a correlation between the pathology and the physio-pathology of TBI.
Interventions
BIOLOGICALBiological Collection
Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
Sponsors
Hopital Universitaire Robert-Debre
University of Cambridge
Mario Negri Institute for Pharmacological Research
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. patient ≥ 18 years old at the time of inclusion 2. Written and informed consent obtained from the family / proxy 3. Patient hospitalized in neuro-ICU following severe TBI with GCS ≤ 8 at admission 4. Intubated / ventilated patient scheduled for external ventricular bypass within 24 hours of hospitalization 5. Absence of contraindications to perform an MRI 6. Patient affiliated to a social security scheme (free State medical aid excluded)
Exclusion criteria
1. Patient under protection of the law (guardianship or tutorship) 2. TBI of ballistic origin 3. Pregnant woman 4. Pre-existing cerebral disease that can bias the MRI scan evaluation 5. Contraindications to the MRI (pace maker, medical device incompatible with MRI, metal plates, ...) 6. Patient with severe impairment of vital and / or life-threatening function with disability prior TBI 7. Neurological antecedent susceptible to interfere with clinical evolution at one year 8. Severe cardiogenic shock 9. Severe respiratory impairment 10. Extra-brain injuries involving immediate life-threatening 11. Hemoglobin level below 9g / dL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin-1 level in blood predict changes in brain volume assessed by quantitative MRI. | Day 42 and 12 months | Brain volume evolution assessed by quantitative MRI between Day 42 and Day 365 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of biomarkers such as Tau protein and beta-amyloid plaques in serum and cerebrospinal fluid (Aβ1-42, T-tau, and P-tau181P and Interleukin 1) | Blood and CSF samples collected at Day1, Day2, Day3, Day5 and Day7 | Plasma and Serum biological collection, multimodal MRI database, clinical database |
Countries
France
Contacts
Primary ContactVincent Degos, PU-PH
Backup ContactGregory Torkomian, Master
Outcome results
None listed